MacroGenics | MGNX - Cash And Equivalent


MacroGenics reported $80.13M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.63B 838M Sep/2025
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Biogen USD 3.86B 1.1B Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
Genmab DKK 1.3B 323M Jun/2025
Geron USD 79.99M 389K Sep/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
J&J USD 18.23B 10.35B Sep/2025
MacroGenics USD 80.13M 50.56M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Xencor USD 28.29M 16.15M Sep/2025